7 hours ago
5
TipRanks
Tue, December 16, 2025 astatine 9:40 AM CST 1 min read
BofA expert Michael Ryskin lowered the firm’s price target connected Tempus AI (TEM) to $80 from $90 and keeps a Neutral standing connected the shares. The steadfast is updating it terms targets for Life Sciences & Diagnostic Tools stocks nether its coverage, the expert tells investors. Headwinds are expected to fade, and markets are expected to normalize successful 2026, steadfast adds. The steadfast believes the biggest upside for the assemblage volition beryllium a instrumentality to spending by Biopharma, starring BofA to favour companies with higher vulnerability to probe and development.
-
Unlock hedge-fund level information and almighty investing tools designed to assistance you marque smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation truthful your portfolio is ever positioned for maximum potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See the apical stocks recommended by analysts >>
Read More connected TEM:
Disclaimer & DisclosureReport an Issue
-
Tempus AI terms people lowered to $80 from $85 astatine JPMorgan
-
Tempus AI, Inc. Class A: Balancing Potential Leadership successful AI-Driven Healthcare with Cautious Hold Rating
-
Tempus AI assumed with an Overweight astatine Morgan Stanley
-
Tempus AI terms people raised to $105 from $96 astatine BTIG
-
Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet connected This USDC Giant
English (CA) · 
English (US) · 
Spanish (MX) ·